HSBC Maintains Hold on Pfizer, Raises Price Target to $30

Benzinga Newsdesk www.benzinga.com Positive 56.8%

Neg 0% Neu 0% Pos 56.8%

HSBC analyst Rajesh Kumar maintains Pfizer (NYSE:PFE) with a Hold and raises the price target from $28 to $30.

Comments

No comments yet. Be the first!